logo
  

Stock Alert: Tenax Surges 60% On Positive Data From Levosimendan Trial

Shares of Tenax Therapeutics, Inc. (TENX) soared over 60% on Tuesday morning after the pharma maker reported positive data from mid-stage trial of levosimendan for treatment in heart disorder.

TENX is currently trading at $2.36, up $0.91 or 62.76%, on the Nasdaq.

Tenax announced positive Phase 2 results for levosimendan to reat pulmonary hypertension and heart failure with preserved ejection fraction.

Levosimendan demonstrated a statistically significant reduction in pulmonary capillary wedge pressure, the primary efficacy analysis, compared to baseline and placebo when the measurements at rest, with legs up and on exercise were combined. Levosimendan also showed significant improvement in 6-minute walk distance compared to placebo.

While there was no significant change in pulmonary capillary wedge pressure during exercise, patients had reductions from baseline at Week 6 in pulmonary artery pressure and right atrial pressure.

Dr. Stuart Rich, Professor of Medicine at the Bluhm Cardiovascular Institute at Northwestern University commented "Levosimendan is the first drug to ever show a favorable mechanism of action with biventricular effects in patients with PH-HFpEF. The consistency of the hemodynamic data and improvement in 6-minute walk demonstrates that levosimendan has great promise as a treatment for PH-HFpEF which has a serious unmet need. The favorable safety profile, especially the absence of any proarrhythmic effects, supports the further development with a phase 3 trial."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
When Can We Expect Starlink to Go Public? This question got an answer from Tesla and SpaceX CEO Elon Musk, who said he will only publicly list SpaceX's satellite internet service Starlink when its revenue is more predictable. Musk was responding to a users tweet, "Any thoughts on Starlink IPO we would love to invest in the future. Any thoughts on first dibs for Tesla retail investors?" John David McAfee, who founded the antivirus software company McAfee Associates, has been found dead in a prison cell in Spain shortly after a Spanish court agreed to extradite him to the US to face tax evasion charges, multiple reports said. He was arrested in Spain in October 2020 after being accused of failing to file tax returns for four years. While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) initiated its adjusted loss and total revenue guidance for the full-year 2022, below analysts' estimates. For fiscal 2022, the company now projects an adjusted loss in a range...
Follow RTT